Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Uroplasty Ramps Up Incontinence Sales Force As Urgent PC Gains More Coverage

This article was originally published in The Gray Sheet

Executive Summary

Uroplasty plans to boost its sales force by roughly 50% by the end of November to seize a growing market for its Urgent PC neuromodulation system following a major payer coverage announcement.

You may also be interested in...

Uroplasty’s Neuromodulator Falls Short On Blue Cross Blue Shield Test

Evidence does not support Uroplasty’s Urgent PC neuromodulation system, a 510(k)-cleared device for treating overactive bladder and symptoms, as an effective treatment option, according to an assessment by the Blue Cross Blue Shield’s Technology Evaluation Center.

News In Brief

FDA Office of Device Evaluation director

CMS News In Brief

Physician imaging cuts finalized


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts